IP Library Granted Patent US 10,793,828
Granted Patent B2
US 10,793,828 · App. 15/415,754 · Granted Oct 6, 2020

Protein enriched microvesicles and methods of making and using the same

Inventors: Michael Haugwitz (Belmont, CA); Thomas Patrick Quinn (Sunnyvale, CA); Andrew Alan Farmer (Los Altos, CA); Montserrat Morell Fernández (Menlo Park, CA)
Assignee: Takara Bio USA, Inc.
C12N5/0602C07K14/005C07K14/43595C07K17/06C12N5/00C12N9/003C12N9/1241C12P21/02C12Y105/01003C07K2319/00C07K2319/70C12N2501/998C12N2760/00022C12N2760/20222
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,793,828
App. No.
15/415,754
Granted
Oct 6, 2020
Kind
B2
Abstract

Protein enriched micro-vesicles and methods of making and using the same are provided. Aspects of the methods include maintaining a cell having a membrane-associated protein comprising a first dimerization domain and a target protein having a second dimerization domain under conditions sufficient to produce a micro-vesicle from the cell, wherein the micro-vesicle includes the target protein. Also provided are cells, reagents and kits that find use in making the micro-vesicles, as well as methods of using the micro-vesicles, e.g., in research and therapeutic applications.

Claims (19)

1. A micro-vesicle comprising:

a membrane-associated chimeric protein comprising a first dimerization domain; and

a target chimeric protein that is not membrane-associated comprising a second dimerization domain,

wherein the first and second dimerization domains are specifically bound to each other in a dimerized complex or the first and second dimerization domains are bound to each other by a single dimerization mediator.

2. The micro-vesicle according to claim 1 , wherein the first and second dimerization domains are specifically bound to each other in the dimerized complex.

3. The micro-vesicle according to claim 1 , wherein first and second dimerization domains are bound to each other by a single dimerization mediator.

4. The micro-vesicle according to claim 3 , wherein the dimerization mediator is a modifiable dimerization mediator.

5. The micro-vesicle according to claim 1 , wherein the micro-vesicle further comprises a micro-vesicle inducer.

6. The micro-vesicle according to claim 5 , wherein the micro-vesicle inducer comprises a viral membrane fusion protein.

7. The micro-vesicle according to claim 6 , wherein the viral membrane fusion protein is VSV-G.

8. The micro-vesicle according to claim 1 , wherein the membrane-associated chimeric protein is selected from the group consisting of a myristoylated protein, a farnesylated protein, a membrane anchor protein, a transmembrane protein and membrane lipid protein.

9. The micro-vesicle according to claim 1 , wherein the first and second dimerization domains are heterodimeric.

10. The micro-vesicle according to claim 1 , wherein the first and second dimerization domains are homodimeric.

11. The micro-vesicle according to claim 1 , wherein the first and second dimerization domains are selected from DmrA and DmrC domains, DmrB domains, DmrD domains, dimerization domains of the dihydrofolate reductase system, dimerization domains of TAg and p53, and dimerization domains of Src Homology 2 and a phosphotyrosine-binding protein.

12. The micro-vesicle according to claim 1 , wherein the micro-vesicle further comprises a second target protein comprising a third dimerization domain.

13. The micro-vesicle according to claim 1 , wherein the target chimeric protein is a research protein selected from the group consisting of: a genomic modification protein, a transcription modulator of an inducible expression system, a member of a signal production system, a hormone, a prohormone, a protease, an enzyme activity modulator, a peptide aptamer, an antibody, a modulator of a protein-protein interaction, and a cellular reprogramming protein.

14. The micro-vesicle according to claim 13 , wherein the research protein is a genomic modification protein.

15. The micro-vesicle according to claim 14 , wherein the genomic modification protein is selected from the group consisting of: a CRE recombinase, a meganuclease, a Zinc-finger nuclease, a clustered regularly interspaced short palindromic repeats/CRISPER associated protein 9 (CRISPR/Cas-9) nuclease and a transcription activator-like (TAL) effector nuclease.

16. The micro-vesicle according to claim 1 , wherein the membrane associated with the membrane-associated protein is separate from a cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2017
From: HAUGWITZ, MICHAEL; QUINN, THOMAS PATRICK; FARMER, ANDREW ALAN; FERNÁNDEZ, MONTSERRAT MORELL
To: CLONTECH LABORATORIES, INC.
Reel/Frame 041754/0016 →
CHANGE OF NAME Recorded Mar 27, 2017
From: CLONTECH LABORATORIES, INC.
To: TAKARA BIO USA, INC.
Reel/Frame 041754/0036 →
Continuity (4)
Division 14278714 · May 15, 2014
Provisional Application 61872115 · Aug 30, 2013
Provisional Application 61833880 · Jun 11, 2013
Related Publication 20170130197A1 · May 11, 2017
Cited By (5)
US 12,202,861 US 12,319,938 US 12,351,814 US 12,351,815 US 12,404,525